Slow-onset, cumulative, mostly invisible. Not a felt nootropic.

• Onset: No acute felt effect. Plasma fatty acids rise within hours; membrane incorporation takes 2-4 weeks for early effects, 8-12 weeks for steady state. Triglyceride drop is measurable on lipid panel by ~6-8 weeks.
• Peak/plateau: After 2-3 months of consistent dosing, observable changes are: less joint stiffness, faster DOMS resolution, sometimes skin texture improvement, lipid panel improvement on next blood draw.
• Taper: Membrane DHA half-life is ~2-3 weeks, so effects fade gradually over 1-2 months after stopping. EPA shorter (1-2 weeks). No withdrawal — just gradual loss of cumulative protection.
• What it does NOT feel like: Not a stimulant, not a mood lifter, not a focus enhancer. The depression-adjunct effect (when responder) takes 6-8 weeks and is modest. Don't dose expecting Tuesday-afternoon-different.

For the user specifically: most likely felt benefits at 2-3 g/day are post-training recovery (less DOMS) and joint mobility. Cardiovascular and brain effects are invisible-but-real on the membrane and inflammatory level.

• Tolerance buildup: Not relevant. No tolerance reported in any trial. Mechanism is structural (membrane incorporation), not receptor-mediated.
• Recommended cycle: None. Daily continuous use is the standard protocol in all clinical trials. Membrane incorporation only reaches steady state at 8-12 weeks; cycling defeats the purpose.
• Reset protocol: Not applicable.

Synergistic with

• astaxanthin (the V4 stack pairing): Highest-leverage pairing in V4/V5 design. Fish oil provides fat vehicle for astaxanthin absorption (2-4× bioavailability boost); astaxanthin's membrane-spanning carotenoid protects DHA from peroxidation in plasma and membrane phospholipids. DHA is the most peroxidation-susceptible fatty acid; without antioxidant cover, supplementation can paradoxically raise oxidative stress markers. Take same softgel, same meal.
• vitamin-e (mixed tocopherols): Foundational lipid-peroxidation chain breaker. Most reputable fish oil products include tocopherols as in-bottle antioxidants. Mixed tocopherols preferred over isolated alpha-tocopherol (preserves gamma-tocopherol's reactive nitrogen species coverage).
• NAC / glutathione precursors: NAC supports GSH synthesis, sustaining the downstream lipid-peroxide clearance pathway (glutathione peroxidase). Mechanism-aligned with no direct interaction.
• statins: Complementary lipid mechanisms — statins lower LDL-C via HMG-CoA reductase inhibition; n-3 PUFAs lower triglycerides via SREBP-1c suppression and apo-CIII reduction. REDUCE-IT was specifically a statin-treated population. No PK interaction. Standard of care for high-CV-risk patients.
• curcumin: Both anti-inflammatory via different mechanisms (n-3 via eicosanoid shift + SPM synthesis; curcumin via NF-κB inhibition). Both fat-soluble; co-administer at the same fat-containing meal.
• vitamin D3 / K2: Both fat-soluble; share the breakfast fat-meal absorption window. No direct biochemical interaction but practical co-stacking.
• CoQ10 / ubiquinol: Mitochondrial-membrane antioxidant. Layered membrane protection. Both fat-soluble.
• creatine: No interaction. Different mechanisms (n-3 membrane biology vs. ATP buffering). Common stack in athletic populations.

Avoid stacking with

• Krill oil simultaneously: Redundant — krill oil delivers the same EPA+DHA as phospholipids vs. triglycerides. Phospholipid form may have ~1.5× per-gram bioavailability but absolute n-3 content per softgel is much lower (~150 mg vs 300-500 mg in concentrated fish oil). Choose one. Krill bonus: contains astaxanthin natively.
• Cod liver oil simultaneously: Adds vitamins A and D to EPA+DHA; chronic high-dose use risks vitamin A toxicity. Use cod liver oil only if D and A intake are otherwise deficient.
• Excess omega-6 (industrial seed oils): Linoleic acid competes for the same elongation/desaturation enzymes (Δ6/Δ5 desaturase) and shifts membrane phospholipid pool back toward arachidonic acid. Effective n-3 status depends on n-3 intake AND n-6 reduction. Omega-6:omega-3 ratio matters more than absolute n-3 dose for some endpoints. Reduce dietary linoleic acid alongside fish oil supplementation.

Neutral / safe co-administration

• BPC-157 — orthogonal mechanisms (n-3 systemic anti-inflammatory; BPC-157 localized tissue repair). Often combined in regenerative protocols.
• Modafinil, bromantane, Adamax/Semax, ALCAR, taurine, theanine, magnesium — no documented interactions.
• Most peptide therapy stacks — no documented interactions.

• Anticoagulants (warfarin, DOACs): Mild antiplatelet effect via reduced thromboxane A2 synthesis. Clinical bleeding risk minimal at <3 g/day in healthy adults; meta-analyses show no significant clinical bleeding increase even with concurrent antiplatelets. Monitor INR if on warfarin; avoid >4 g/day perioperatively. Pause 5-7 days pre-elective surgery.
• Aspirin / antiplatelets (P2Y12 inhibitors): Mild additive effect on platelet aggregation. Clinically tolerated; widely used together post-MI. Bleeding events rare at OTC doses.
• Statins: Synergistic, no PK interaction (see Stacking). Standard of care combination for high-CV-risk patients with elevated TG.
• Thiazide diuretics / antihypertensives: Mild additive BP-lowering effect (~2-5 mmHg systolic at 2-4 g/day). Not clinically significant in normotensive young adults.
• Beta-blockers / antiarrhythmics: No documented interaction. Caution at high dose (>2 g/day) in patients with AFib history given the AFib signal.
• Orlistat (lipase inhibitor): Reduced absorption of fat-soluble compounds including fish oil. Separate by 2+ hours.
• Cholestyramine / colesevelam (bile acid sequestrants): May reduce fish oil absorption. Separate by 4+ hours.

Several validated polymorphisms modulate fish oil response:

• FADS1 / FADS2 (fatty acid desaturase) variants — affect endogenous conversion of ALA → EPA → DHA. Common minor allele (rs174537 T allele) reduces conversion efficiency. Consequence: minor allele carriers benefit more from preformed EPA/DHA supplementation (vs. ALA from flax). ~30% of European ancestry carry minor allele homozygous; higher in some Asian populations. Worth noting from the user's June 2026 23andMe — if FADS1 minor allele, this strengthens the supplementation rationale.

• APOE4 carriers — Yassine 2017 and follow-up trials suggest APOE4 carriers may not absorb / incorporate DHA into the brain as efficiently as non-carriers. Earlier and higher-dose DHA supplementation (pre-symptomatic) may be required for cognitive protection. If 23andMe returns APOE4: dose unchanged at 2-3 g/day combined but consider DHA-leaning ratio and continue indefinitely.

• ALOX5 / ALOX12 / ALOX15 variants — modulate leukotriene and SPM synthesis from EPA/DHA substrate. Specific variants associated with stronger or weaker anti-inflammatory response. Limited consumer-genetic data.

• PPAR-α / PPAR-γ variants — n-3 PUFAs are PPAR ligands. Variants modulate hepatic lipid response (triglyceride drop magnitude varies by genotype).

• GPR120 (FFAR4) — receptor for long-chain FFAs including EPA/DHA. Variants associated with metabolic response variability.

When 23andMe results land, the actionable variants for this compound are FADS1/FADS2 (confirms supplementation rationale) and APOE4 (modifies dose / ratio / urgency).

The user's recommendation: Sports Research Triple Strength Omega-3 (iHerb) — fits the existing iHerb V4 order channel, ~$15-25/mo at 2 g/day, IFOS 5-star, rTG form, perfect pairing with the existing Sports Research astaxanthin softgel at the same breakfast meal. Alternative if iHerb shipping is bottlenecked: Costco Kirkland Signature for budget volume. Avoid bulk-bin generic.

• Baseline (before starting):

  • Omega-3 index (gold-standard membrane EPA+DHA% — OmegaQuant, $50). Target >8% (cardioprotective range; US baseline ~4-5%).
  • Lipid panel: total chol, LDL-C, HDL-C, triglycerides (key).
  • ApoB (better atherogenic-particle measure than LDL-C).
  • hsCRP (inflammation).
  • Optional: oxidized LDL, MDA — better lipid-peroxidation proxies.
  • Blood pressure (mild BP-lowering effect at 2-4 g/day).
  • EKG if AFib history.

• During use (every 6 months):

  • Omega-3 index (looking for rise to >8%; takes 3-4 months at 2 g/day to plateau).
  • Triglycerides (looking for 20-30% drop at 8-12 weeks).
  • hsCRP (looking for ↓).
  • ApoB (looking for stable/slight ↓).
  • Subjective: post-training recovery, joint stiffness, skin clarity.

• Post-cycle: N/A — no cycling.

For the user specifically: tie this into the June 2026 baseline panel he already has scheduled. Add omega-3 index (OmegaQuant kit, ~$50, mail-in finger-prick). At the 6-month follow-up, check omega-3 index again — the dose-response curve confirms whether 2-3 g/day is sufficient for >8% target or whether dose needs escalation.